The valuation of a NDA using a 6-fold compound option
- 31 January 2004
- journal article
- Published by Elsevier in Research Policy
- Vol. 33 (1) , 41-51
- https://doi.org/10.1016/s0048-7333(03)00089-1
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- THE OPTION VALUE OF AN EARLY‐STAGE BIOTECHNOLOGY INVESTMENTJournal of Applied Corporate Finance, 2002
- The valuation of compound optionsPublished by Elsevier ,2002
- New drug development in the United States from 1963 to 1999Clinical Pharmacology & Therapeutics, 2001
- Risks in new drug development: Approval success rates for investigational drugsClinical Pharmacology & Therapeutics, 2001
- Real-Options Valuation for a Biotechnology CompanyCFA Magazine, 2000
- The option value of advanced R & DEuropean Journal of Operational Research, 1997
- Option pricing: A simplified approachJournal of Financial Economics, 1979
- The Pricing of Options and Corporate LiabilitiesJournal of Political Economy, 1973